Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.

TitleMechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody.
Publication TypeJournal Article
Year of Publication2023
AuthorsGupta A, Kao KS, Yamin R, Oren DA, Goldgur Y, Du J, Lollar P, Sundberg EJ, Ravetch JV
JournalNat Commun
Volume14
Issue1
Pagination2853
Date Published2023 May 18
ISSN2041-1723
KeywordsAnimals, Glycosylation, Immunoglobulin Fc Fragments, Immunoglobulin G, Mice, Polysaccharides, Receptors, IgG
Abstract

Immunoglobulin G (IgG) antibodies contain a complex N-glycan embedded in the hydrophobic pocket between its heavy chain protomers. This glycan contributes to the structural organization of the Fc domain and determines its specificity for Fcγ receptors, thereby dictating distinct cellular responses. The variable construction of this glycan structure leads to highly-related, but non-equivalent glycoproteins known as glycoforms. We previously reported synthetic nanobodies that distinguish IgG glycoforms. Here, we present the structure of one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1. Upon binding, the elongated CDR3 loop of X0 undergoes a conformational shift to access the buried N-glycan and acts as a 'glycan sensor', forming hydrogen bonds with the afucosylated IgG N-glycan that would otherwise be sterically hindered by the presence of a core fucose residue. Based on this structure, we designed X0 fusion constructs that disrupt pathogenic afucosylated IgG1-FcγRIIIa interactions and rescue mice in a model of dengue virus infection.

DOI10.1038/s41467-023-38453-1
Alternate JournalNat Commun
PubMed ID37202422
PubMed Central IDPMC10195009
Grant ListP30 GM133893 / GM / NIGMS NIH HHS / United States
P30 CA008748 / CA / NCI NIH HHS / United States
S10 RR027037 / RR / NCRR NIH HHS / United States
U19 AI111825 / AI / NIAID NIH HHS / United States
T32 GM007739 / GM / NIGMS NIH HHS / United States

Person Type: